1
/
of
0
FDA FAERS Reports for COBENFY (Xanomeline + Trospium) – Jan 1 to Mar 7, 2025 – CSV Requested
FDA FAERS Reports for COBENFY (Xanomeline + Trospium) – Jan 1 to Mar 7, 2025 – CSV Requested
Regular price
$69.00 USD
Regular price
Sale price
$69.00 USD
Unit price
/
per
Original Request: I request complete reports of all adverse events submitted to the FAERS database for COBENFY (branded name, marketed by Bristol-Myers Squibb Company) or xanomeline and trospium chloride (generic names) between January 1, 2025, and March 7, 2025. If available, please provide the documents electronically.
Tags: Pharma, FAERS, 2025
Tags: Pharma, FAERS, 2025
Couldn't load pickup availability
- Status: Pending Fast-Track Request
- Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity
NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. IMPORTANT: The FDA FOIA office operations are currently suspended. We are happy to make the request but do not know when we will receive a response. Learn more about Fast-Track Requests here.
View full details